NCT Number: NCT02512003
Pilot Study of the Fantom Bioresorbable Scaffold (FANTOM I)
The FANTOM I pilot study is intended to assess safety of the Fantom Bioresorbable Coronary Scaffold in native coronary arteries.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patient has evidence of myocardial ischemia or a positive functional study
- Patient has a normal CK-MB
- Target lesion has a visually estimated stenosis of ≥50% and <100%
- Target lesion is located in a native coronary artery with average reference vessel diameter ≥ 2.7mm and ≤ 3.3mm
- Target lesion length must be ≤ 14mm
Exclusion criteria
- Patient has experienced a myocardial infarction (CK-MB or Troponin > 5 X ULN) within 72 hours of the procedure
- Patient has a left ventricular ejection fraction < 25%
- Patient has unprotected lest main coronary disease with ≥50% stenosis
- The target vessel is totally occluded (TIMI Flow 0 or 1)
- Target lesion involves a bifurcation (a lesion with a side branch ≥ 2.0 mm in diameter containing a ≥ 50% stenosis).
- Target lesion is located within a bypass graft
- Target lesion has possible or definite thrombus
Treatment and study plan
Primary outcomes
-
Ischemia-driven Target Lesion Revascularization (TLR)
Time frame: 4 months
Percent of Patients with TLR at 4 months
Secondary outcomes
-
Quantitative Coronary Angiography (QCA) derived parameters
Time frame: 4 months
Late Loss
-
Quantitative Coronary Angiography (QCA) derived parameters
Time frame: 4 months
Restenosis Rate
-
Quantitative Coronary Angiography (QCA) derived parameters
Time frame: 4 months
% Diameter Stenosis
-
Quantitative Coronary Angiography (QCA) derived parameters
Time frame: 4 months
Minimum Lumen Diameter
-
Quantitative Coronary Angiography (QCA) derived parameters
Time frame: 4 months
Neointimal Volume
-
Intravascular Ultrasound (IVUS) derived parameters
Time frame: 4 months
Late Loss
-
Intravascular Ultrasound (IVUS) derived parameters
Time frame: 4 months
Restenosis Rate
-
Intravascular Ultrasound (IVUS) derived parameters
Time frame: 4 months
% Diameter Stenosis
-
Intravascular Ultrasound (IVUS) derived parameters
Time frame: 4 months
Minimum Lumen Diameter
-
Intravascular Ultrasound (IVUS) derived parameters
Time frame: 4 months
Neointimal Volume
-
Major Adverse Cardiac Events
Time frame: 12, 24, 36, 48 and 60 months
Death, Q-Wave Myocardial Infarction, Non Q-Wave Myocardial Infarction (CK-MB > 5x normal), Target Vessel Revascularization
-
Target Lesion Revascularization (TLR)
Time frame: 12, 24, 36, 48 and 60 months
Percentage of patients with TLR at each time point
-
Target Vessel Revascularization
Time frame: 12, 24, 36, 48 and 60 months
Percentage of patients with TVR at each time point
-
Target Vessel Failure (TVF)
Time frame: 12, 24, 36, 48 and 60 months
Percentage of patients with TVF at each time point
-
Acute Technical Success
Time frame: Day 0
Percentage of patients with successful acute delivery and deployment of the device
-
Procedural Success
Time frame: 30 days
Percentage of patients with angiographic success (final diameter stenosis <50% without occurrence of MACE)
-
Optical Coherence Tomography (OCT) Imaging on a Subset of Patients
Time frame: 4 months
Qualitative measures in a subset of patients
Sponsors and collaborators
Lead sponsor
REVA Medical, Inc.
Industry
Registry information
Official study title
Pilot Study of the REVA Sirolimus-Eluting Bioresorbable Coronary Scaffold
Acronym: FANTOM I
Important dates
- Study start
- 2014
- Primary completion
- 2015
- Study completion
- 2020
- First posted
- Jul 30, 2015
- Registry last updated
- Mar 29, 2023
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
CES1 Carriers in the PAPI Study
NCT03188705
Arterial Occlusive Diseases, Arteriosclerosis
Lancaster, Pennsylvania, United States
View Trial DetailsImpact of Cardiac Rehabilitation on Patient Outcomes
NCT07468955
Arterial Occlusive Diseases, Arteriosclerosis
Kütahya, Center, Turkey (Türkiye)
View Trial DetailsA Sugar-Sweetened Beverage Reduction Intervention for Native American Men
NCT06029517
Arterial Occlusive Diseases, Arteriosclerosis
Buffalo, New York, United States
View Trial DetailsSafety and Effectiveness of Agent Paclitaxel-Coated PTCA Balloon Catheter. (AGENT Japan SV)
NCT04058990
Arterial Occlusive Diseases, Arteriosclerosis
Kitakyushu, Fukuoka, Japan
View Trial Details